You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Johnson and Johnson
McKinsey
Boehringer Ingelheim
AstraZeneca

Last Updated: October 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,297,346

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,297,346 protect, and when does it expire?

Patent 7,297,346 protects NUVIGIL and PROVIGIL and is included in two NDAs.

Protection for NUVIGIL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-one patent family members in twenty-eight countries.

Summary for Patent: 7,297,346
Title:Pharmaceutical formulations of modafinil
Abstract:The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof.
Inventor(s): Corvari; Vincent (Carmel, IN), Grandolfi; George (Millford, OH), Parikh; Alpa (Hockessin, DE)
Assignee: Cephalon Inc. (Frazer, PA)
Application Number:10/155,913
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,297,346
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;

Drugs Protected by US Patent 7,297,346

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-001 Jun 15, 2007 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-002 Mar 26, 2009 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-003 Jun 15, 2007 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-005 Mar 26, 2009 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-004 Jun 15, 2007 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-001 Dec 24, 1998 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-002 Dec 24, 1998 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,297,346

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 033910   Start Trial
Argentina 041242   Start Trial
Austria 357228   Start Trial
Austria 434435   Start Trial
Australia 2002318155   Start Trial
Australia 2003270563   Start Trial
Brazil 0210085   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Johnson and Johnson
Boehringer Ingelheim
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.